Fig. 4: Loss of DDI2 sensitizes cells to chemical and genetic ferroptosis.
From: Activating the NFE2L1-ubiquitin-proteasome system by DDI2 protects from ferroptosis
a Cell viability in EA.hy926 cells treated with 5 µM NFV and 10 µM ferrostatin for 20 h. b Immunoblot of NFE2L1 in wild-type (Parental WT) and DDI2 knockout (KO) EA.hy926 cells treated 9 h with 10 µM Ferrostatin (Fer-1) and indicated concentrations of RSL3, and 3 h with 100 nM bortezomib (BTZ). c Cell viability of DDI2 KO versus WT EA.hy926 cells after 20 h of treatment with 5 µM RSL3. d Cell viability of SSMD cells (GPX4 mut) and healthy controls (GPX4 WT) after siRNA-mediated silencing of NFE2L1 and DDI2. e Immunoblot of 95 kD cleaved form of NFE2L1 in WT and DDI2 KO EA.hy926 cells transfected with WT NFE2L1 and NFE2L1-8ND mutant plasmids followed by 9 h treatment with 5 µM RSL3 and 100 nM BTZ. f Cell viability of DDI2 KO cells transfected with WT NFE2L1 and NFE2L1-8ND mutant plasmids followed by 9 h treatment with 5 µM RSL3.
